Charles River Laboratories International Inc

NYSE:CRLHealthcareCBOE:SPESGNASDAQ:NQUSMG

$300.02−0.04%At closeAt close · Tue 20 Oct · ≈ AED 1,101.82 · Market cap $14.32B · Next earnings Wed 4 Nov · Extended $303.03 +1.00%

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	36.7%	37.7%	36.8%	36.4%	32.9%	30.5%	—	—
Operating margin	14.8%	16.7%	16.4%	14.9%	5.6%	12.6%	12.6%	+0.0 pts
Net margin	12.5%	11.0%	12.2%	11.5%	0.3%	−3.6%	−3.5%	+0.1 pts
EBITDA margin	26.3%	23.2%	24.8%	25.0%	14.3%	10.2%	—	—
Return on equity	17.2%	15.4%	16.3%	13.2%	0.3%	−4.6%	−4.4%	+0.1 pts
Return on assets	6.6%	5.6%	6.4%	5.8%	0.1%	−2.0%	−2.0%	+0.0 pts
Return on capital employed	9.3%	9.8%	10.0%	8.6%	3.5%	8.4%	—	—
Debt / equity	1.0×	1.3×	1.0×	0.9×	0.8×	1.0×	1.0×	−1.5%
Debt / assets	39.3%	45.6%	40.7%	37.4%	36.2%	43.0%	—	—
Interest coverage	5.0×	8.0×	11.0×	4.5×	1.8×	4.7×	—	—
Current ratio	1.4×	1.2×	1.3×	1.5×	1.4×	1.3×	1.3×	+0.0%
Quick ratio	1.2×	1.0×	1.1×	1.2×	1.1×	1.0×	—	—
Cash ratio	0.3×	0.2×	0.2×	0.3×	0.2×	0.2×	0.2×	+0.0%
Asset turnover	0.5×	0.5×	0.5×	0.5×	0.5×	0.6×	—	—
Inventory turnover	10.0×	11.1×	9.8×	6.9×	9.8×	9.3×	—	—
Receivables turnover	4.7×	5.4×	5.3×	5.3×	5.6×	5.7×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—

Margins, returns, leverage and liquidityUpdated 27 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.